16,280 results match your criteria infliximab


Evaluating various radiographic methods of shoulder joint damage in patients with rheumatoid arthritis receiving biological disease-modifying antirheumatic drugs.

Arch Rheumatol 2021 Sep 12;36(3):349-359. Epub 2020 Dec 12.

Department of Orthopaedic Surgery, Faculty of Medicine, University of Toyama, Toyama, Japan.

Objectives: This study aims to clarify shoulder joint damage in rheumatoid arthritis patients receiving biological disease-modifying antirheumatic drugs (bDMARDs) and the relationship between joint damage and clinical factors.

Patients And Methods: In this retrospective study conducted between April 2005 and December 2008, 36 shoulders in 19 patients (2 males, 17 females; mean age: 58.9 years; range 42 to 75 years) were evaluated at baseline and two years after the initiation of bDMARD therapy with infliximab (n=14) or etanercept (n=5). Read More

View Article and Full-Text PDF
September 2021

A rare localization of tuberculosis under infliximab treatment: Testicular involvement.

Turk J Phys Med Rehabil 2021 Sep 1;67(3):374-377. Epub 2021 Sep 1.

Department of Pathology, Namık Kemal University, School of Medicine, Tekirdağ, Turkey.

Infliximab is an inhibitory of tumor necrosis factor-alpha which is used successfully for the treatment of inflammatory bowel disease and rheumatic disease. It has various side effects including injection-induced reactions, immunosuppression, demyelinating diseases, and cardiac effects. One of the most serious side effects is tuberculosis. Read More

View Article and Full-Text PDF
September 2021

Risk of immunomediated adverse events and loss of response to infliximab in elderly patients with inflammatory bowel disease. A cohort study of the ENEIDA registry.

J Crohns Colitis 2021 Dec 3. Epub 2021 Dec 3.

Hospital Universitario de Burgos, Burgos.

Background: Immunomediated adverse events (IAEs) are the most frequently reported infliximab-related adverse events. Combination therapy may reduce their incidence, although this strategy is not recommended in elderly patients.

Aims: To compare the rates of infliximab-related IAE and loss of response (LOR) in elderly and younger patients. Read More

View Article and Full-Text PDF
December 2021

Positioning infliximab and vedolizumab in the treatment of moderate-to-severe ulcerative colitis.

Gastroenterology 2021 Dec 2. Epub 2021 Dec 2.

Division of Gastroenterology and Hepatology, Department of Internal Medicine, Michigan Medicine, Ann Arbor, MI, USA; VA Center for Clinical Management Research, VA Ann Arbor Health Care System, Ann Arbor, MI, USA; Institute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor, MI, USA. Electronic address:

View Article and Full-Text PDF
December 2021

Flare-up of generalized pustular psoriasis combined with systemic capillary leak syndrome after coronavirus disease 2019 mRNA vaccination.

J Dermatol 2021 Dec 3. Epub 2021 Dec 3.

Department of Dermatology, Ehime University Graduate School of Medicine, Toon, Japan.

Generalized pustular psoriasis (GPP) is characterized by acute flare-ups induced by various factors, but few reports have described GPP onset or flare-up induced by vaccination. To our knowledge, only three such cases following coronavirus disease 2019 (COVID-19) vaccination have been reported. We herein report a case of GPP flare-up after COVID-19 mRNA vaccination. Read More

View Article and Full-Text PDF
December 2021

Incidence of COVID-19 in patients treated with infliximab compared with patients treated with rituximab.

RMD Open 2021 12;7(3)

Divison of Rheumatology, Department of Internal Medicine, Geneva University Hospitals, Geneve, Switzerland

Objective: To determine whether patients with inflammatory autoimmune diseases treated with rituximab (RTX) have more severe forms of COVID-19 compared with patients treated with anticytokine therapies, such as Tumour Necrosis Factor (TNF) inhibitors.

Methods: We included all patients who were on either RTX or infliximab (IFX) in two Swiss cantons during the first wave of the COVID-19 pandemic. We collected self-reported symptoms compatible with COVID-19, PCR-confirmed diagnoses of COVID-19 and the evolution of COVID-19 infections. Read More

View Article and Full-Text PDF
December 2021

Chronic Inflammatory Demyelinating Polyneuropathy in Patients With Crohn's Disease on Infliximab Therapy.

Cureus 2021 Oct 25;13(10):e19041. Epub 2021 Oct 25.

Neurology Department, King Abdullah Medical City, Mecca, SAU.

Crohn's disease (CD) is a chronic inflammatory disorder of the gastrointestinal tract that is frequently accompanied by systemic complications including peripheral neuropathies. Anti-tumor necrosis factor-alpha agents such as infliximab are an established treatment for immune-mediated diseases. However, they have been associated with adverse effects, including local reactions, infections, congestive heart failure, malignancies, and, rarely, they can cause neurological adverse effects on the central nervous system, as well as peripheral nervous system demyelination. Read More

View Article and Full-Text PDF
October 2021

Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis.

Lancet Gastroenterol Hepatol 2021 Nov 29. Epub 2021 Nov 29.

INSERM NGERE and Department of Hepatogastroenterology, Nancy University Hospital, Lorraine University, Vandoeuvre-lés-Nancy, France. Electronic address:

Background: There is a growing armamentarium for the treatment of moderate-to-severe ulcerative colitis. We aimed to compare the relative efficacy and safety of biologics and small molecule drugs for the treatment of patients with moderate-to-severe ulcerative colitis.

Methods: In this systematic review and network meta-analysis, we searched MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials without language restrictions for articles published between Jan 1, 1990, and July 1, 2021. Read More

View Article and Full-Text PDF
November 2021

[Wish to conceive while using infliximab: considerations].

Ned Tijdschr Geneeskd 2021 Sep 16;165. Epub 2021 Sep 16.

Bijwerkingencentrum Lareb, Afd. Moeders van Morgen, 's Hertogenbosch.

Background: Inflammatory bowel disease affects many women of childbearing potential. Women who wish to conceive face many uncertainties. Effects of their medications and their disease may interfere with normal pregnancy and development of the child. Read More

View Article and Full-Text PDF
September 2021

Drug Survival of Biologics in Patients With Hidradenitis Suppurativa.

JAMA Dermatol 2021 Dec 1. Epub 2021 Dec 1.

Department of Dermato-Venereology & Wound Healing Centre, Bispebjerg Hospital, Copenhagen, Denmark.

Importance: Biologics are important in treating patients with hidradenitis suppurativa (HS). However, to our knowledge, data on their real-life performance and treatment patterns in HS are limited.

Objective: To examine the drug survival of biologic therapies for HS in a real-world setting. Read More

View Article and Full-Text PDF
December 2021

Differential serum-intestinal dynamics of infliximab and adalimumab in inflammatory bowel disease patients.

J Crohns Colitis 2021 Nov 24. Epub 2021 Nov 24.

Department of Gastroenterology, Rambam Health Care Campus, Haifa, Israel.

Background And Aims: Therapeutic drug monitoring is used to guide anti-TNF therapy. However, the association between serum drug levels (SDL), TNF-bound and free anti-TNF in the target tissue are incompletely defined. We aimed to assess the interactions between these parameters in inflammatory bowel disease (IBD) patients. Read More

View Article and Full-Text PDF
November 2021

A biomimetic nanocomposite made of a ginger-derived exosome and an inorganic framework for high-performance delivery of oral antibodies.

Nanoscale 2021 Nov 30. Epub 2021 Nov 30.

Department of Pharmaceutics, School of Pharmacy, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang, Liaoning Province 110016, PR China.

For inflammatory bowel disease (IBD) therapy, systemic exposure of anti-TNF-α antibodies brought by current clinical injection always causes serious adverse effects. Colon-targeted delivery of anti-TNF-α antibodies through the oral route is of great importance but remains a formidable challenge. Here, we reported a biomimetic nanocomposite made of a ginger-derived exosome and an inorganic framework for this purpose. Read More

View Article and Full-Text PDF
November 2021

Steroid-Free Deep Remission At One Year Does Not Prevent Crohn's Disease Progression: Long-Term Data From the TAILORIX Trial.

Clin Gastroenterol Hepatol 2021 Nov 26. Epub 2021 Nov 26.

Department of Gastroenterology, Inserm U1256, Nancy University Hospital, Lorraine University, Vandoeuvre-les-Nancy, France.

Objective: Crohn's disease (CD) patients included in the TAILORIX trial started infliximab in combination with an immunosuppressant for one year. The aim of the present study was to determine the long-term disease course beyond the study period.

Design: We compared the outcomes of patients that did or did not reach the primary endpoint of the TAILORIX trial, defined as sustained corticosteroid-free clinical remission from weeks 22 through 54, with no ulcers on ileo-colonoscopy at week 54. Read More

View Article and Full-Text PDF
November 2021

Serum oncostatin M is a potential biomarker of disease activity and infliximab response in inflammatory bowel disease measured by chemiluminescence immunoassay.

Clin Biochem 2021 Nov 26. Epub 2021 Nov 26.

Department of Laboratory Medicine, Zhejiang University School of Medicine Second Affiliated Hospital, Hangzhou 310009, Zhejiang Province, China. Electronic address:

Background: Although endoscopy is the gold standard to assess disease activity and infliximab efficacy in inflammatory bowel disease (IBD), the invasive, costly, and time-consuming procedure limits its routine applications. We aimed to investigate the clinical value of serum oncostatin M (OSM) as a surrogate biomarker.

Methods: Fifty healthy controls, 34 non-IBD patients, and 189 IBD patients who were pre-infliximab treatment (n = 122) or in infliximab maintenance (n = 67) were enrolled. Read More

View Article and Full-Text PDF
November 2021

CT-P13 SC for the treatment of rheumatoid arthritis.

Authors:
Rene Westhovens

Expert Rev Clin Immunol 2021 Nov 27. Epub 2021 Nov 27.

Skeletal Biology and Engineering Research Center, Department of Development and Regeneration KU Leuven, Rheumatologist UZ Leuven. Belgium.

Introduction: : Management of Rheumatoid Arthritis(RA) has improved following implementation of early intensive treat to target recommendations and the availability of different biologicals. Most experience is with TNF blockers but challenges remain in the efficacy/safety balance, immunogenicity and long term drug survival as well as availability and affordability despite introduction of biosimilars. : We provide an overview of the development of CT-P13 SC, based on infliximab biosimilar CT-P13 IV. Read More

View Article and Full-Text PDF
November 2021

Successful and unsuccessful management for indolent Kawasaki disease.

Pediatr Int 2021 Nov 27. Epub 2021 Nov 27.

Department of Pediatrics, Keio University School of Medicine, Tokyo, Japan.

View Article and Full-Text PDF
November 2021

Chronic Recurrent Multifocal Osteomyelitis Associated with Crohn Disease: A Potential Role of Exclusion Diet? Comment on Starz et al. The Modification of the Gut Microbiota via Selected Specific Diets in Patients with Crohn's Disease. 2021, , 2125.

Nutrients 2021 Nov 10;13(11). Epub 2021 Nov 10.

Pediatric Gastroenterology Unit, Maggiore Hospital, Azienda USL, 40133 Bologna, Italy.

The efficacy of diet and its influence on gut microbiome composition has been largely demonstrated in inflammatory bowel disease (IBD). Little is known about its potential in the management of extraintestinal manifestations. We report a successful application of Crohn disease exclusion diet (CDED) in association with infliximab and methotrexate, as salvage therapy in a child affected by chronic recurrent multifocal osteomyelitis (CRMO) and Crohn disease (CD) resistant to optimized therapy. Read More

View Article and Full-Text PDF
November 2021

Impairment of CD4+ T and Memory B Cell Responses but Normal Memory CD8+T-Cell Activation on Crohn's Disease after COVID-19 Vaccination: A Twin Case.

Viruses 2021 10 24;13(11). Epub 2021 Oct 24.

Instituto de Tecnologia em Imunobiológicos, Bio-Manguinhos, Fundação Oswaldo Cruz, FIOCRUZ, Rio de Janeiro 21040-900, Brazil.

Vaccines to prevent the impact of SARS-CoV-2 are now available, including for patients with autoimmune diseases. However, there is no information about how inflammatory bowel disease (IBD) treatment could impact the cellular and humoral immune responses. This study evaluated SARS-CoV-2-specific humoral and cellular responses after vaccination with a two-dose schedule in a Crohn's disease patient treated with Infliximab (10 mg/kg); we included comparisons with a monozygotic twin. Read More

View Article and Full-Text PDF
October 2021

The Effect of TNF-α Inhibitors on Nail Psoriasis and Psoriatic Arthritis-Real-World Data from Dermatology Practice.

J Pers Med 2021 Oct 25;11(11). Epub 2021 Oct 25.

Department of Rheumatology and Clinical Immunology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, 10117 Berlin, Germany.

Patients with psoriatic arthritis (PsA) often develop joint symptoms years after their initial diagnosis of psoriasis disease; therefore, dermatologists should test for and detect PsA early. In this study, we focused on patients with psoriasis with both nail and joint disease being treated with tumor necrosis factor-α inhibitors by dermatologists. We performed a noninterventional, prospective, multicenter, and open-label study to evaluate the effectiveness of adalimumab, etanercept, or infliximab over 24 months of continuous therapy in patients with moderate to severe plaque-type psoriasis (Pso) and PsA. Read More

View Article and Full-Text PDF
October 2021

Infliximab Efficacy May Be Linked to Full TNF-α Blockade in Peripheral Compartment-A Double Central-Peripheral Target-Mediated Drug Disposition (TMDD) Model.

Pharmaceutics 2021 Nov 1;13(11). Epub 2021 Nov 1.

EA 4245 "Transplantation, Immunology, Inflammation", Université de Tours, 37044 Tours, France.

Infliximab is an anti-TNF-α monoclonal antibody approved in chronic inflammatory bowel diseases (IBD). This study aimed at providing an in-depth description of infliximab target-mediated pharmacokinetics in 133 IBD patients treated with 5 mg/kg infliximab at weeks 0, 2, 14, and 22. A two-compartment model with double target-mediated drug disposition (TMDD) in both central and peripheral compartments was developed, using a rich database of 26 ankylosing spondylitis patients as a reference for linear elimination kinetics. Read More

View Article and Full-Text PDF
November 2021

Biomarkers for Optimization and Personalization of Anti-TNFs in Pediatric Inflammatory Bowel Disease.

Pharmaceutics 2021 Oct 26;13(11). Epub 2021 Oct 26.

Servicio de Farmacia, Instituto de Investigación Sanitaria Gregorio Marañón, Hospital General Universitario Gregorio Marañón, 28007 Madrid, Spain.

The use of biological drugs has improved outcomes in pediatric inflammatory bowel disease (IBD). Prediction of the response to biological drugs would be extremely useful in IBD, and even more so in children, who are still growing physically and psychologically. Specific clinical, biochemical, and genetic parameters are considered predictive of response to biological drugs, although few studies have been carried out in children with IBD. Read More

View Article and Full-Text PDF
October 2021

Quantitative Glycan Profiling of Therapeutic Monoclonal Antibodies Performed by Middle-Up Level HILIC-HRMS Analysis.

Pharmaceutics 2021 Oct 20;13(11). Epub 2021 Oct 20.

Institute of Pharmaceutical Sciences of Western Switzerland (ISPSO), University of Geneva, CMU-Rue Michel-Servet 1, 1211 Geneva, Switzerland.

The identification and accurate quantitation of the various glycoforms contained in therapeutic monoclonal antibodies (mAbs) is one of the main analytical needs in the biopharmaceutical industry, and glycosylation represents a crucial critical quality attribute (CQA) that needs to be addressed. Currently, the reference method for performing such identification/quantitation consists of the release of the -glycan moieties from the mAb, their labelling with a specific dye (e.g. Read More

View Article and Full-Text PDF
October 2021

Antiviral Activities of Halogenated Emodin Derivatives against Human Coronavirus NL63.

Molecules 2021 Nov 11;26(22). Epub 2021 Nov 11.

Faculty of Chemistry and Chemical Technology, University of Ljubljana, Večna pot 113, 1000 Ljubljana, Slovenia.

The current COVID-19 outbreak has highlighted the need for the development of new vaccines and drugs to combat Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2). Recently, various drugs have been proposed as potentially effective against COVID-19, such as remdesivir, infliximab and imatinib. Natural plants have been used as an alternative source of drugs for thousands of years, and some of them are effective for the treatment of various viral diseases. Read More

View Article and Full-Text PDF
November 2021

Immunogenicity of BNT162b2 Vaccine in Patients with Inflammatory Bowel Disease on Infliximab Combination Therapy: A Multicenter Prospective Study.

J Clin Med 2021 Nov 18;10(22). Epub 2021 Nov 18.

Department of Genetics and Bioinformatics, Dasman Diabetes Institute (DDI), Dasman 15462, Kuwait.

Background: Vaccination is a promising strategy to protect vulnerable groups like inflammatory bowel disease (IBD) patients against COVID-19 and associated severe outcomes. COVID-19 vaccine clinical trials excluded IBD patients taking infliximab with azathioprine or 6-mercaptopurine (infliximab combination). Therefore, we sought to evaluate serologic responses to COVID-19 vaccination with the mRNA vaccine, BNT162b2, in patients with IBD receiving infliximab combination therapy compared with healthy participants. Read More

View Article and Full-Text PDF
November 2021

Levels of Biosimilar Infliximab during and after Induction Treatment in Crohn's Disease and Ulcerative Colitis-A Prospective Polish Population Study.

J Clin Med 2021 Nov 15;10(22). Epub 2021 Nov 15.

Department of Gastroenterology with IBD, Unit of Clinical Hospital 2 in Rzeszow, Lwowska 60, 35-301 Rzeszow, Poland.

Background: Primary lack or secondary loss of response to therapy with infliximab is a significant problem. This study aimed to evaluate the response to treatment in patients with Crohn's disease (CD) and ulcerative colitis (UC) achieving therapeutic and sub-therapeutic trough levels of biosimilar infliximab (CT-P13).

Results: A total of 65 patients (32 with CD and 33 with UC) were recruited. Read More

View Article and Full-Text PDF
November 2021

Risk Factors of Cytomegalovirus Reactivation in Ulcerative Colitis Patients: A Meta-Analysis.

Diagnostics (Basel) 2021 Oct 21;11(11). Epub 2021 Oct 21.

Department of General Surgery, Tianjin Medical University General Hospital, 154 Anshan Road, Heping District, Tianjin 300052, China.

Cytomegalovirus (CMV) infection is associated with exacerbation of disease activity in patients with ulcerative colitis (UC). However, the risk factors for CMV reactivation in this population remain debatable. This meta-analysis was performed to identify the risk factors for CMV reactivation in UC patients. Read More

View Article and Full-Text PDF
October 2021